These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 24378784)
21. Prescribing in an age of "wonder drugs". Herzberg D MD Advis; 2011; 4(2):14-8. PubMed ID: 21637177 [No Abstract] [Full Text] [Related]
22. Market entry of biosimilar low-molecular-weight heparins in Europe: opportunities and challenges. Simoens S; Huys I Semin Thromb Hemost; 2013 Apr; 39(3):250-7. PubMed ID: 23235959 [TBL] [Abstract][Full Text] [Related]
23. Chemical probes: A shared toolbox. Scott AR Nature; 2016 May; 533(7602):S60-1. PubMed ID: 27167393 [No Abstract] [Full Text] [Related]
24. [Antibiotics - quo vadit?]. Lode HM; Stahlmann R Dtsch Med Wochenschr; 2012 Jun; 137(24):1314-6. PubMed ID: 22669701 [No Abstract] [Full Text] [Related]
25. Patents discipline is key to securing big pharma investment. Jones N Drug Discov Today; 2012 Jan; 17(1-2):1-2. PubMed ID: 22138380 [No Abstract] [Full Text] [Related]
26. Baywatch: San Francisco. Smaglik P Nature; 2004 Feb; 427(6975):658-9. PubMed ID: 14961125 [No Abstract] [Full Text] [Related]
27. Access to patient-level trial data--a boon to drug developers. Eichler HG; Pétavy F; Pignatti F; Rasi G N Engl J Med; 2013 Oct; 369(17):1577-9. PubMed ID: 24144395 [No Abstract] [Full Text] [Related]
28. Regulatory forum opinion piece: differences between protein-based biologic products (biotherapeutics) and chemical entities (small molecules) of relevance to the toxicologic pathologist. Leach MW Toxicol Pathol; 2013 Jan; 41(1):128-36. PubMed ID: 22744226 [TBL] [Abstract][Full Text] [Related]
29. Comparability and biosimilarity: considerations for the healthcare provider. Lee JF; Litten JB; Grampp G Curr Med Res Opin; 2012 Jun; 28(6):1053-8. PubMed ID: 22519391 [TBL] [Abstract][Full Text] [Related]
30. The best companies bare all. Jacobs T Nat Biotechnol; 2004 Nov; 22(11):1363. PubMed ID: 15529156 [No Abstract] [Full Text] [Related]
31. Upcycling drugs for brain-related diseases: a sustainable future for targeted drug delivery. de Boer M; Visser CC; Gaillard PJ Ther Deliv; 2013 Apr; 4(4):435-8. PubMed ID: 23557284 [No Abstract] [Full Text] [Related]
32. Setting the stage for cancer startups. Cancer Discov; 2012 Oct; 2(10):OF11. PubMed ID: 23071034 [TBL] [Abstract][Full Text] [Related]
34. EFPIA-PhRMA's principles for clinical trial data sharing have been misunderstood. Doshi P BMJ; 2013 Aug; 347():f5164. PubMed ID: 23963563 [No Abstract] [Full Text] [Related]
35. Biotechnology in the Medicon Valley. Frank L Nature; 2002 Dec; 420(6916 Suppl):A27, A29, A31 passim. PubMed ID: 12501124 [No Abstract] [Full Text] [Related]
37. Grant review opens up Texas-sized rift. Wadman M Nature; 2012 Jun; 486(7402):169-71. PubMed ID: 22699589 [No Abstract] [Full Text] [Related]
38. Traditional drug-discovery model ripe for reform. Cressey D Nature; 2011 Mar; 471(7336):17-8. PubMed ID: 21368796 [No Abstract] [Full Text] [Related]
39. Deal watch: Trends in discovery externalization. Mayhew S Nat Rev Drug Discov; 2010 Mar; 9(3):183. PubMed ID: 20190781 [No Abstract] [Full Text] [Related]
40. How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development. Perakslis ED; Van Dam J; Szalma S Clin Pharmacol Ther; 2010 May; 87(5):614-6. PubMed ID: 20376001 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]